A randomized trial to determine the impact of a digestion resistant starch composition on the gut microbiome in older and mid-age adults
A randomized trial to determine the impact of a digestion resistant starch composition on the gut microbiome in older and mid-age adults
复制标题
DOI：
10.1016/j.clnu.2017.03.025
复制
发表时间：
2018-06-01
影响因子：
6.3
通讯作者：
Lix, Lisa M.
中科院分区：
文献类型：
--
作者：
Alfa, Michelle J.;Strang, David;Lix, Lisa M.
背景：老年人通常饮食缺乏抗性淀粉（RS），这被认为会导致肠道微生物群失调，可能导致肠道结肠细胞恶化。目的：主要目的是评估老年人（ELD; >= 70岁）与中年人（MID； 30-50岁）相比是否存在微生物群失调，然后确定每日服用MSPrebiotic (R) （a RS）或安慰剂超过3个月对肠道微生物群组成的影响。次要目标包括评估ELD和MID加拿大成年人的粪便短链脂肪酸（SCFA）和炎症标志物。设计：这是一项前瞻性、安慰剂对照、随机、双盲研究。在入组时以及随机分配到安慰剂组或MSPrebiotic组(R)后的6周、10周和14周收集粪便。对粪便中提取的DNA进行16S rRNA测序，进行微生物组分析。粪便SCFA分析采用气相色谱法。结果：有42名ELD和42名MID参与者随机分配到安慰剂或MSPrebiotic (R)组，他们完成了研究。与入组时的MID相比，ELD中变形菌（大肠杆菌/志贺氏菌）的丰度显著更高（p < 0.001），而在服用MSPrebiotic (R) 12周后未观察到这一点。与安慰剂组相比，ELD组和MID组双歧杆菌数量显著增加（p分别为0.047和0.006）。与安慰剂相比，服用MSPrebiotic (R)的ELD患者的粪便SCFA丁酸水平有小幅但显著的增加。结论：研究数据表明，MSPrebiotic (R)符合益生元标准，无需额外补充益生菌即可刺激ELD和MID中内源性双歧杆菌的丰度增加。MSPrebiotic (R)的摄入也消除了基线时在ELD中观察到的肠道变形菌群的生态失调。临床试验注册号：NCT01977183列在NIH网站：clinicaltrials .gov.完整的试验方案可向通讯作者索取。核苷酸序列登录号：本研究产生的16S rRNA测序数据和元数据已提交至NCBI sequence Read Archive （SRA: http://www.ncbi.nlm.nih.gov/bioproject/381931）。(C) 2017作者。Elsevier Ltd.出版。这是一篇基于CC BY-NC-ND许可（http://creativecommons.org/licensesiby-nc-nd/4.0/）的开放获取文章。
Background: The elderly often have a diet lacking resistant starch (RS) which is thought to lead to gut microbiome dysbiosis that may result in deterioration of gut colonocytes.Objective: The primary objective was to assess if elderly (ELD; >= 70 years age) had microbiome dysbiosis compared to mid-age (MID; 30-50 years age) adults and then determine the impact of daily consumption of MSPrebiotic (R) (a RS) or placebo over 3 months on gut microbiome composition. Secondary objectives included assessment of stool short-chain fatty acids (SCFA) and inflammatory markers in ELD and MID Canadian adults.Design: This was a prospective, placebo controlled, randomized, double-blinded study. Stool was collected at enrollment and 6, 10 and 14 weeks after randomization to placebo or MSPrebiotic (R). Microbiome analysis was done using 16S rRNA sequencing of DNA extracted from stool. SCFA analysis of stool was performed using gas chromatography.Results: There were 42 ELD and 42 MID participants randomized to either placebo or MSPrebiotic (R) who completed the study. There was significantly higher abundance of Proteobacteria (Escherichia coli/Shigella) in ELD compared to MID at enrollment (p < 0.001) that was not observed after 12 weeks of MSPrebiotic (R) consumption. There was a significant increase in Bifidobacterium in both ELD and MID compared to placebo (p = 0.047 and 0.006, respectively). There was a small but significant increase in the stool SCFA butyrate levels in the ELD on MSPrebiotic (R) versus placebo.Conclusions: The study data demonstrated that MSPrebiotic (R) meets the criteria of a prebiotic and can stimulate an increased abundance of endogenous Bifidobacteria in both ELD and MID without additional probiotic supplementation. MSPrebiotic (R) consumption also eliminated the dysbiosis of gut Proteobacteria observed in ELD at baseline.Clinical Trial Registry Number: NCT01977183 listed on NIH website: ClinicalTrials.gov.The full trial protocol is available on request from the corresponding author.Nucleotide sequence accession numbers: The 16S rRNA sequencing data and metadata generated in this study have been submitted to the NCBI Sequence Read Archive (SRA: http://www.ncbi.nlm.nih.gov/bioproject/381931). (C) 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licensesiby-nc-nd/4.0/).